> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Foresee Pharma NDA Approved for Prostate Cancer
- URL: https://www.fdaweb.com/foresee-pharma-nda-approved-for-prostate-cancer/
- Published: 2021-05-27T12:00:00.000Z
- Updated: 2026-09-14T17:00:53.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149417

FDA has approved a Foresee Pharmaceuticals NDA for Camcevi (leuprolide mesylate) 42 mg, a six-month subcutaneous depot formulation for treating advanced prostate cancer. Approval was based on data from a Phase 3 study in 137 advanced prostate carcinoma patients. The primary efficacy end point was the percentage of subjects with suppression of serum testosterone, according to the company. The primary efficacy endpoint was successfully achieved in 97% of subjects, it says. Camcevi has been exclusively licensed to Accord BioPharma for commercialization in the U.S.